American Journal of Clinical Nutrition, Vol 61, 843-847, Copyright © 1995 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis

BC Portal, MJ Richard, HS Faure, AJ Hadjian and AE Favier
Laboratoire de Biochimie, UFR des Sciences Pharmaceutiques et Biologiques, Domaine de la Merci, La Tronche, France.

Cystic fibrosis often combines an infectious pathology with a syndrome of malabsorption, both potentially capable of favoring the deleterious effects of reactive oxygen species. This study was a simultaneous evaluation of the main antioxidant systems dependent on micronutrients and of lipid peroxidation products in 27 children with cystic fibrosis and 17 healthy children. Plasma of cystic fibrosis patients showed very low concentrations of beta-carotene (0.30 +/- 0.2 vs 1.63 +/- 0.5 mumol/g cholesterol, P < 0.0001) and a lower activity of selenium- dependent glutathione peroxidase (263.6 +/- 42 vs 296.9 +/- 57 U/L, P = 0.028). In parallel, the higher plasma concentrations of organic hydroperoxides (171.5 +/- 54.4 vs 122.6 +/- 23.3 mumol/L, P = 0.001) and of thiobarbituric acid reactants (2.9 +/- 0.6 vs 2.4 +/- 0.3 mumol/L, P = 0.004) reflected oxidative stress in this pathology. In addition, in these patients the major substrates of lipoperoxidation were significantly lower, whether they be linoleic acid (2.26 +/- 0.8 vs 3.60 +/- 0.9 mmol/L, P < 0.0001) or arachidonic acid (0.55 +/- 0.2 vs 0.74 +/- 0.2 mmol/L, P = 0.006). These results suggested that nutritional deficiencies resulting from malabsorption could considerably amplify disorders related to toxicity of reactive oxygen species. These nutritional deficits could also be aggravated by the destruction of antioxidant compounds by the inflammatory process.

This article has been cited by other articles:

				A. J. Kettle, T. Chan, I. Osberg, R. Senthilmohan, A. L. P. Chapman, T. J. Mocatta, and J. S. Wagener Myeloperoxidase and Protein Oxidation in the Airways of Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1317 - 1323. [Abstract] [Full Text] [PDF]

				A. Werner, M. E. J. Bongers, M. J. Bijvelds, H. R. de Jonge, and H. J. Verkade No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis J. Lipid Res., December 1, 2004; 45(12): 2277 - 2286. [Abstract] [Full Text] [PDF]

				J. M. Wright, P. L. Zeitlin, L. Cebotaru, S. E. Guggino, and W. B. Guggino Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins Physiol Genomics, January 15, 2004; 16(2): 204 - 211. [Abstract] [Full Text] [PDF]

				L. G. Wood, D. A. Fitzgerald, and M. L. Garg Hypothesis: Vitamin E Complements Polyunsaturated Fatty Acids in Essential Fatty Acid Deficiency in Cystic Fibrosis J. Am. Coll. Nutr., August 1, 2003; 22(4): 253 - 257. [Abstract] [Full Text] [PDF]

				L. G Wood, D. A Fitzgerald, A. K Lee, and M. L Garg Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function Am. J. Clinical Nutrition, January 1, 2003; 77(1): 150 - 159. [Abstract] [Full Text] [PDF]

				L. G Wood, D. A Fitzgerald, P. G Gibson, D. M Cooper, and M. L Garg Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients Am. J. Clinical Nutrition, April 1, 2002; 75(4): 668 - 675. [Abstract] [Full Text] [PDF]

				L. W. Velsor, A. van Heeckeren, and B. J. Day Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L31 - L38. [Abstract] [Full Text] [PDF]

				L. G. Wood, D. A. Fitzgerald, P. G. Gibson, D. M. Cooper, C. E. Collins, and M. L. Garg Oxidative Stress in Cystic Fibrosis: Dietary and Metabolic Factors J. Am. Coll. Nutr., April 1, 2001; 20(2): 157 - 165. [Abstract] [Full Text] [PDF]

				S Renner, R Rath, P Rust, S Lehr, T. Frischer, I Elmadfa, and I Eichler Effects of {beta}-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis Thorax, January 1, 2001; 56(1): 48 - 52. [Abstract] [Full Text]

				G. CIABATTONI, G. DAVI, M. COLLURA, L. IAPICHINO, F. PARDO, A. GANCI, R. ROMAGNOLI, J. MACLOUF, and C. PATRONO In Vivo Lipid Peroxidation and Platelet Activation in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1195 - 1201. [Abstract] [Full Text] [PDF]

				P. PAREDI, S. A. KHARITONOV, D. LEAK, P. L. SHAH, D. CRAMER, M. E. HODSON, and P. J. BARNES Exhaled Ethane Is Elevated in Cystic Fibrosis and Correlates with Carbon Monoxide Levels and Airway Obstruction Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1247 - 1251. [Abstract] [Full Text]

				P Paredi, P L Shah, P Montuschi, P Sullivan, M E Hodson, S A Kharitonov, and P J Barnes Increased carbon monoxide in exhaled air of patients with cystic fibrosis Thorax, October 1, 1999; 54(10): 917 - 920. [Abstract] [Full Text]

				J. Hull and A. H Thomson Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis Thorax, December 1, 1998; 53(12): 1018 - 1021. [Abstract] [Full Text]